Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Journal Mobile Options
Table of Contents
Vol. 5, No. 3-4, 2008
Issue release date: March 2008
Section title: Aging
Free Access
Neurodegenerative Dis 2008;5:261–263
(DOI:10.1159/000113719)

Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System

Wesnes K.A.
Cognitive Drug Research Ltd., Goring-on-Thames, and Human Cognitive Neuroscience Unit, Northumbria University, Newcastle upon Tyne, UK; Brain Sciences Institute, Swinburne University, Hawthorn, Vic., Australia
email Corresponding Author

Prof. Keith A Wesnes, PhD

Cognitive Drug Research Ltd., CDR House

Gatehampton Road

Goring-on-Thames RG8 0EN (UK)

Tel. + 44 1491 878 700, Fax +44 1491 878 701, E-Mail keithw@cognitivedrugresearch.com


References

  1. Wesnes K, Harrison J: The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues Clin Neurosci 2003;5:77–88.
  2. Ferris S, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H, Geldmacher D, Bodick N: Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):34–38.
    External Resources
  3. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK: The Cognitive Drug Research computerised assessment system for demented patients: a validation study. Int J Geriatr Psychiatry 1991;6:95–102.
    External Resources
  4. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R: Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183–192.
  5. Wesnes KA, Harrison J, Edgar C, Pincock C: The sensitivity and reliability of the Cognitive Drug Research computerised cognitive assessment system to disease progression and treatment response in Alzheimer’s disease. Int Psychogeriatr 2005;17(suppl 2):154.
  6. Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes K, Tekin S, Aarsland D: Attentional deficits affect activities of daily living in dementia associated with PD. J Neurol Neurosurg Psychiatry 2006;77:1136–1142.
  7. Mohr E, Walker D, Randolph C, Sampson M, Mendis T: The utility of clinical trial batteries in the measurement of Alzheimer’s and Huntington’s dementia. Int Psychogeriatr 1996;8:397–411.
  8. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, Ballard CG: Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease and vascular dementia. Neurology 2000;54:1616–1625.
  9. Zaffalon M, Wesnes K, Petrini O: Reliable diagnosis of dementia by the naïve credal classifier inferred from incomplete cognitive data. Artif Intell Med 2003;29:61–79.
  10. Wesnes K: The role of attention deficits in the cognitive pathology of dementia. Alzheimer Insights 2001;7:1–4.
  11. Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S: Early onset effects of galantamine treatment on attention in patients with Alzheimer’s disease. Curr Med Res Opin 2005;21:1423–1429.
  12. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
  13. Emre M, Aarsland D, Albanese A, et al: Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351:2509–2518.
  14. Wesnes KA, McKeith IG, Edgar C, Ferrara R, Emre M, Lane R: Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005;65:1654–1656.
  15. Rowan E, McKeith IG, Saxby BK, Newby, Daniel S, Sanders J, Wesnes KA: Effects of donepezil on central processing speed and attentional measures in Parkinson’s disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23:161–167.
  16. Cummings JL: Commentary, cholinesterase inhibitors: expanding applications. Lancet 2000;356:2024–2036.
  17. Press DZ: Parkinson’s disease dementia – A first step? N Engl J Med 2004;351:2547–2549.